donepezil has been researched along with curcumin in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 37 (67.27) | 24.3611 |
| 2020's | 18 (32.73) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Li, W; Li, X; Wang, B; Wang, Y; Wang, Z | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Manral, A; Maqbool, M; Saini, V; Shandilya, A; Tiwari, M | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Kumari, S; Manral, A; Mishra, CB; Saini, V; Tiwari, M | 1 |
| Kong, LY; Li, F; Li, XM; Wang, J; Wang, XB; Wang, ZM; Wu, JJ | 1 |
| Cai, P; Kong, LY; Liu, QH; Wang, XB; Wang, ZM; Wu, JJ; Xu, DQ; Yang, XL | 1 |
| Kumari, S; Lynn, AM; Manral, A; Mishra, CB; Prakash, A; Saini, V; Tiwari, M | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Boni, MS; Castro, NG; Coelho, MM; da Silva, FM; da Silva, ML; Dardenne, LE; de Melo, IS; de Paula, CT; Dias, KS; Dos Santos, T; Giusti, FC; Giusti-Paiva, A; Guedes, IA; Guimarães, MJ; Morroni, F; Neves, GA; Pruccoli, L; Souza, IN; Tarozzi, A; Veloso, CC; Viegas, C | 1 |
| Ding, Y; Lan, JS; Liu, J; Liu, Y; Miao, ZY; Xie, SS; Yang, J; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Sang, Z; Song, Q; Tan, Z; Wang, T; Xu, R; Zhang, X | 1 |
| Ahmed, W; Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mumtazuddin, S; Tiwari, M | 1 |
| Ding, Y; Hou, JW; Kang, P; Lan, JS; Liu, Y; Xie, SS; Zhang, T; Zhang, XY | 1 |
| Cai, P; Kong, LY; Li, F; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Chen, Q; Digiacomo, M; Nesi, G; Pi, R; Rapposelli, S; Sestito, S; Wang, S; Yang, X | 1 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| Cai, P; Fang, SQ; Kong, LY; Liu, QH; Wang, XB; Yang, HL; Yang, XL | 1 |
| Catenacci, L; Cavaletti, G; Collina, S; Coniglio, S; Curti, D; Liedl, KR; Malacrida, A; Monteleone, S; Pace, V; Paolillo, M; Rossi, D; Rossino, G; Rui, M; Schepmann, D; Scuteri, A; Sorrenti, M; Urban, E; Venturini, L; Wünsch, B | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Ahmed, W; Gusain, S; Hoda, N; Kumar, J; Raza, MK; Shalini, S; Tiwari, M; Umar, T | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Gusain, S; Hoda, N; Kumar, J; Raza, MK; Seth, P; Shalini, S; Tiwari, M; Umar, T | 1 |
| Gusain, S; Hoda, N; Kumar, J; Raza, MK; Shalini, S; Tiwari, M; Umar, T | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Ji, J; Peng, Y; Rakesh, KP; Wang, S; Xu, M; Zhu, L | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Cheng, X; Liu, W; Ma, Q; Sang, Z; Shi, J; Tan, Z; Wang, K; Wei, R; Yu, L; Zhao, Y; Zhu, G | 1 |
| Cheng, X; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z | 1 |
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Arora, S; Attri, S; Bhagat, K; Kaur Gulati, H; Kaur, P; Kumar, N; Mohinder Singh Bedi, P; Sharma, S; Singh, A; Singh, H; Vir Singh, J | 1 |
| Du, H; Jiang, X; Liu, S; Ma, F; Ma, M; Xu, H | 1 |
| Aksakal, F; Dogruer, DS; Ercetin, T; Erdogan, M; Gulcan, HO; Kilic, B; Sagkan, RI | 1 |
| Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
| Cao, Z; Deng, Y; Sang, Z; Song, Q; Tan, Z; Zhang, L | 1 |
| Chowdhury, SR; Fu, L; Gu, J; Hu, Y; Jiang, F; Lam, C; Lei, S; Lu, D; Tavallaie, MS; Wang, J | 1 |
| Chen, S; Du, J; Li, R; Li, Z; Liu, T; Xing, S | 1 |
| Li, J; Liu, D; Liu, W; Shi, T; Wang, D; Wang, Y; Wang, Z; Yin, G; Zhang, H | 1 |
| Deng, Y; Liu, X; Liu, Z; Shi, Y; Song, Q; Tan, Z; Yu, G; Zhang, H; Zhong, F | 1 |
| He, Y; Liu, W; Mi, J; Sang, Z; Wu, A; Yang, J; Zhou, Y; Zhu, G | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Chen, L; Lei, Z; Sun, J; Sun, X; Wang, Y; Yue, S | 1 |
| Akinyemi, AJ; Oboh, G; Ogunsuyi, O; Oyeleye, SI | 1 |
| Batool, Z; Haider, S; Naqvi, F; Perveen, T; Saleem, S | 1 |
| Aydemir, O; Bocekci, VG; Cam, ME; Duruksu, G; Ertas, B; Guler, E; Gunduz, O; Gurbuz, F; Ozcan, GS; Sahin Cam, C; Topal, F; Yazir, Y | 1 |
| Al-Khalileh, NM; Al-Rifai, NM; Darras, FH; El-Barghouthi, MI; Zahra, JA | 1 |
2 review(s) available for donepezil and curcumin
| Article | Year |
|---|---|
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Triazoles | 2019 |
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
53 other study(ies) available for donepezil and curcumin
| Article | Year |
|---|---|
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; Cyclic Nucleotide Phosphodiesterases, Type 4; Inflammation; Ligands; Male; Memory; Models, Molecular; Neurons; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Protein Aggregates; Rats; Rats, Wistar; Resorcinols | 2015 |
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Stilbenes; Structure-Activity Relationship | 2016 |
Development of cyanopyridine-triazine hybrids as lead multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Molecular Targeted Therapy; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Pyridines; Triazines | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Humans; Hydrogen Peroxide; Indans; Kinetics; Microscopy, Electron, Transmission; Neuroprotective Agents | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Electrophorus; Horses; Humans; Indans; Indoles; Iron; Kinetics; Melatonin; Molecular Docking Simulation; Peptide Fragments; Piperidines; Protein Multimerization; Rats; Zinc | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Copper; Donepezil; Drug Design; Humans; Indans; Kinetics; Liver; Mice; Models, Molecular; Peptide Fragments; Piperidines; Protein Aggregates; Protein Conformation | 2016 |
Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Cell Line; Donepezil; Drug Delivery Systems; Drug Design; Humans; Indans; Ligands; Microscopy, Electron, Transmission; Molecular Dynamics Simulation; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregation, Pathological; Protein Binding | 2017 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease.
Topics: Acrylates; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Indans; Male; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Neurons; Neuroprotective Agents; Piperidines; Structure-Activity Relationship | 2017 |
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Donepezil; Drug Design; Electrophorus; Humans; Indans; Mice; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Piperidines; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Drug Design; Flavones; Humans; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; PC12 Cells; Rats; Scopolamine; Structure-Activity Relationship | 2017 |
Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Triazines | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; Butyrylcholinesterase; Cell Death; Cholinergic Agents; Cholinesterase Inhibitors; Cinnamates; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats; Structure-Activity Relationship | 2017 |
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biological Products; Butyrylcholinesterase; Cell Death; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Free Radical Scavengers; Glutamic Acid; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rivastigmine; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Design; Hippocampus; Humans; Indoles; Ligands; Memory Disorders; Mice; Quinolines | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butylated Hydroxytoluene; Cell Line; Cholinergic Agents; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Mice; Molecular Structure; Neuroprotective Agents; PC12 Cells; Piperidines; Protein Aggregates; Rats; Structure-Activity Relationship | 2018 |
Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
Topics: Acetylcholinesterase; Animals; Antioxidants; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Guinea Pigs; Humans; Mice; Molecular Docking Simulation; Neurodegenerative Diseases; Neuroprotective Agents; Rats; Reactive Oxygen Species; Receptors, sigma; Sigma-1 Receptor; Small Molecule Libraries | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of
Topics: | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Carboxylic Ester Hydrolases; Chelating Agents; Cholinesterase Inhibitors; Copper; Crystallography, X-Ray; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Microscopy, Electron, Transmission; Molecular Docking Simulation; Pyrazoles; Pyridines; Spectrometry, Fluorescence | 2019 |
Naphthalene-triazolopyrimidine hybrid compounds as potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Anti-Anxiety Agents; Drug Design; Humans; Naphthalenes | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apigenin; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Ligands; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Rats; Rivastigmine; Structure-Activity Relationship; Zebrafish | 2020 |
The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Development; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Structure-Activity Relationship; Zebrafish | 2020 |
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Female; Male; Membranes, Artificial; Mice; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Permeability; Protein Aggregation, Pathological; Random Allocation; Rats | 2020 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Humans; Molecular Structure; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; Triazoles | 2020 |
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Benzoxazoles; Butyrylcholinesterase; Cell Proliferation; Cells, Cultured; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Horses; Humans; Mice; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Structure-Activity Relationship; Thiazoles | 2021 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Cell Survival; Chalcone; Drug Design; Humans; Kinetics; Metals; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship | 2021 |
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Biphenyl Compounds; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Oxadiazoles; Picrates; Protein Aggregates; Structure-Activity Relationship | 2022 |
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Drug Design; Humans; Male; Maze Learning; Molecular Docking Simulation; Neuroprotective Agents; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tryptamines | 2022 |
Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cholinesterase Inhibitors; Drug Design; Mice; Protein Aggregates; Structure-Activity Relationship | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Drug Development; Flavanones; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2022 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Rats | 2022 |
Anti-amnestic Effect of Curcumin in Combination with Donepezil, an Anticholinesterase Drug: Involvement of Cholinergic System.
Topics: Adenosine Deaminase; Animals; Brain; Catalase; Cholinergic Neurons; Cholinesterase Inhibitors; Curcumin; Donepezil; Drug Synergism; Glutathione; Indans; Lipid Peroxidation; Male; Maze Learning; Memory Disorders; Nitric Oxide; Piperidines; Rats; Recognition, Psychology; Scopolamine; Superoxide Dismutase | 2017 |
A comparative study showing greater effects of curcumin compared to donepezil on memory function in rats.
Topics: Acetylcholinesterase; Animals; Antioxidants; Behavior, Animal; Brain; Cholinesterase Inhibitors; Cognition; Curcumin; Donepezil; Dose-Response Relationship, Drug; GPI-Linked Proteins; Lipid Peroxidation; Male; Maze Learning; Memory; Nootropic Agents; Oxidative Stress; Rats, Wistar | 2019 |
A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers.
Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Curcumin; Donepezil; Glycogen Synthase Kinase 3 beta; Memantine; Nanofibers; Rats; Spectroscopy, Fourier Transform Infrared | 2022 |
Synthesis, biological evaluation, and computational studies of
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Curcumin; Donepezil; Humans; Molecular Docking Simulation; Pain; Structure-Activity Relationship | 2023 |